TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24996454

Group type: EXPERIMENTAL
Intervention: Consensus guideline target volume delineation atlas
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not following the atlas)
Number of subjects: 13
Study: 23471817

Group type: EXPERIMENTAL
Intervention: Syringe with clip
Number of subjects: 149

Group type: COMPARATOR
Intervention: Syringe without clip
Number of subjects: 149

Group type: COMPARATOR
Intervention: Dosing cup
Number of subjects: 149
Study: 21679320

Group type: EXPERIMENTAL
Intervention: Alpine skiing training (12 weeks, 2-3 times a week, ∼3.5 hours per session)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (inactive, n=20, 67 ± 4 years)
Number of subjects: 22
Study: 18504547

Group type: EXPERIMENTAL
Intervention: 250 ml white wine (approximately 25 g alcohol/day)
Number of subjects: 36
Study: 17323844

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (24 sessions of 30 minutes each over 16 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 12699806

Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 130

Group type: COMPARATOR
Intervention: Vacuum delivery
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Forceps delivery (after exclusion of 'failed vacuum')
Number of subjects: 130
Study: 11063191

Group type: EXPERIMENTAL
Intervention: Atropine in a smoke-free environment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atropine in a smoking environment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline BP in a smoke-free environment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline BP in a smoking environment
Number of subjects: 17
Study: 8883001

Group type: EXPERIMENTAL
Intervention: High-intensity (HI) exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-intensity (LI) exercise
Number of subjects: 8
Study: 1373337

Group type: EXPERIMENTAL
Intervention: High dose of high-osmolarity ionic contrast medium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose of low-osmolarity non-ionic contrast medium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lower fixed dose of low-osmolarity non-ionic contrast medium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Additional radiograph during abdominal compression
Number of subjects: 60
Study: 3533471

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg body weight)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neostigmine (5.0 micrograms/kg body weight)
Number of subjects: 48
Study: 30217232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 29231517

Group type: EXPERIMENTAL
Intervention: Multi-directional stimulation technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 60
Study: 24297951

Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium before and after oxaliplatin
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo before and after oxaliplatin
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Calcium/magnesium before and placebo after
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Calcium/magnesium
Number of subjects: 353
Study: 22323092

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered intravenously, titrated according to a weight-adjusted dosing nomogram to a target aPTT of 1.5-2 times the upper limit of normal (approximately 50-70 s), median treatment duration of 42 hours.
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently below <50 s for recurrent ischemic events.
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently above >70 s for major hemorrhagic events.
Number of subjects: 4985
Study: 20196118

Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Number of subjects: 863

Group type: COMPARATOR
Intervention: 16 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: 24 weeks of treatment in genotype 2
Number of subjects: 863

Group type: COMPARATOR
Intervention: 16 weeks of treatment in genotype 2
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: 24 weeks of treatment in genotype 3
Number of subjects: 863

Group type: COMPARATOR
Intervention: 16 weeks of treatment in genotype 3
Number of subjects: 863
Study: 18613251

Group type: EXPERIMENTAL
Intervention: Empirical patient-level data extrapolation methodology
Number of subjects: 23000

Group type: EXPERIMENTAL
Intervention: Novel combination of models estimating hazard rate
Number of subjects: 23000
Study: 16818836

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 14520130

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nefazodone and Fluoxetine
Number of subjects: 16
Study: 10919932

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid‐enriched oil (supplement)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo oil (control)
Number of subjects: 36
Study: 9026626

Group type: EXPERIMENTAL
Intervention: Moderate physical effort (occupational and non-occupational)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Controls (no specific intervention mentioned)
Number of subjects: 372
Study: 1364197

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam (n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.05 mg/kg vecuronium (n = 8)
Number of subjects: 15
Study: 3840276

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 55
Study: 31898510

Group type: EXPERIMENTAL
Intervention: Internet‐delivered behavioural intervention (BIP TIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internet‐delivered education programme
Number of subjects: 0
Study: 31185129

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 38
Study: 28625628

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT)
Number of subjects: 260

Group type: COMPARATOR
Intervention: No thoracic radiotherapy (no TRT)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Presence of liver metastases
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Presence of bone metastases
Number of subjects: 260
Study: 25837164

Group type: EXPERIMENTAL
Intervention: Maze procedure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maze procedure with LAA preservation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maze procedure with LAA resection
Number of subjects: 12
Study: 23130748

Group type: EXPERIMENTAL
Intervention: T+PDE5i
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 21574710

Group type: EXPERIMENTAL
Intervention: theoretically tailored print-based PA promotion intervention
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: enhanced tailoring addressing 5 additional SCT constructs
Number of subjects: 248
Study: 19211468

Group type: EXPERIMENTAL
Intervention: Care coordination programs (nurses providing patient education and monitoring, mostly via telephone, with an average of two contacts per month)
Number of subjects: 18309

Group type: EXPERIMENTAL
Intervention: Care coordination programs
Number of subjects: 18309

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 18309
Study: 16533098

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (23-session intervention)
Number of subjects: 208
Study: 12974184

Group type: EXPERIMENTAL
Intervention: saccharosum + sennosid-B solution
Number of subjects: 157

Group type: COMPARATOR
Intervention: Na-picosulphate
Number of subjects: 157
Study: 11094009

Group type: EXPERIMENTAL
Intervention: Subglottic low-frequency jet ventilation (15 breaths/min)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Subglottic combined-frequency jet ventilation (600 and 15 breaths/min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Supraglottic combined-frequency jet ventilation
Number of subjects: 37
Study: 9353611

Group type: EXPERIMENTAL
Intervention: Ergoset (quick-release bromocriptine)
Number of subjects: 0
Study: 1288892

Group type: EXPERIMENTAL
Intervention: Essentiale forte
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 3905529

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy without drainage
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control subjects without any stomach disease
Number of subjects: 190
Study: 31773541

Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 25
Study: 28301197

Group type: EXPERIMENTAL
Intervention: Comparative Regression Discontinuity Design with a Non-equivalent Comparison Group (CRD-CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic Regression Discontinuity (RD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized Control Trial
Number of subjects: 0
Study: 28965122

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (7.20 mg ED50 for motor block)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Plain bupivacaine (10.05 mg ED50 for motor block)
Number of subjects: 38
Study: 26313312

Group type: EXPERIMENTAL
Intervention: Smoke-free Homes (SFH) educational intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 213
Study: 23208128

Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: EGFR mutation
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: KRAS/EGFR wild type
Number of subjects: 1935

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1935

Group type: COMPARATOR
Intervention: EGFR tyrosine kinase inhibitors (TKI)
Number of subjects: 1935

Group type: COMPARATOR
Intervention: Chemotherapy among the three groups
Number of subjects: 1935
Study: 22030221

Group type: COMPARATOR
Intervention: EPA-DHA plus ALA (n = 1009)
Number of subjects: 4116

Group type: COMPARATOR
Intervention: EPA-DHA (n = 1007)
Number of subjects: 4116

Group type: COMPARATOR
Intervention: ALA (n = 1022)
Number of subjects: 4116
Study: 18671684

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16949943

Group type: EXPERIMENTAL
Intervention: Bioenergetic Synchronization Technique (n = 40)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Diversified technique spinal manipulation (n = 38)
Number of subjects: 81
Study: 12562319

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 141

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 141
Study: 10224735

Group type: EXPERIMENTAL
Intervention: 18 sessions of twice-weekly exposure therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18 sessions of twice-weekly exposure therapy followed by 16 sessions of behavioral family therapy (BFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study: 8630312

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyloestradiol/150 micrograms desogestrel
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyloestradiol/150 micrograms desogestrel
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyloestradiol/75 micrograms gestodene
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All three groups (30 micrograms ethinyloestradiol/desogestrel, 20 micrograms ethinyloestradiol/desogestrel, 30 micrograms ethinyloestradiol/gestodene)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All oral contraceptives studied
Number of subjects: 67
Study: 1910103

Group type: EXPERIMENTAL
Intervention: Discontinuous regimen (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Overlapping regimen (20 patients)
Number of subjects: 40
Study: 6356972

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl concentrations below 10 micrograms/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl with 1:200 000 adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More dilute solutions of epidural fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl with adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl concentrations
Number of subjects: 0
Study: 27930447

Group type: EXPERIMENTAL
Intervention: Carbohydrate and caffeine (CHO-C) (40 g·h + 3 mg·kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate (CHO; 40 g·h)
Number of subjects: 8
Study: 29938739

Group type: EXPERIMENTAL
Intervention: New ProTaper Next (PTN) instruments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Used ProTaper Next (PTN) instruments
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: New Horizen (HZ) instruments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Used Horizen (HZ) instruments
Number of subjects: 25
Study: 26517621

Group type: EXPERIMENTAL
Intervention: Sclerotherapy- group (continued endoscopic ligation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sclerotherapy+ group (combined ligation and sclerotherapy with lauromacrogol)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 24738883

Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination (FC) of tafluprost 0.0015%/timolol 0.5%
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-fixed combination (NFC) of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups (FC and NFC)
Number of subjects: 400
Study: 22569139

Group type: EXPERIMENTAL
Intervention: Tailored-print intervention group (3 tailored newsletters over 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted-print intervention group (physical activity guidebook)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard recommendation control group (brochure detailing physical activity guidelines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 19691873

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Active rTMS (8 weeks)
Number of subjects: 21
Study: 17346247

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15791418

Group type: EXPERIMENTAL
Intervention: NON‐OCC (normal muscle blood flow)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: OCC (occluded muscle blood flow)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NON‐OCC and OCC (both conditions)
Number of subjects: 22
Study: 12149201

Group type: EXPERIMENTAL
Intervention: COL3A1‐4 carriers
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: COL3A1‐4
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: COL3A1‐3
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1857
Study: 10519471

Group type: EXPERIMENTAL
Intervention: Precontemplation stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contemplation stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparation stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action stage
Number of subjects: 0
Study: 8771145

Group type: EXPERIMENTAL
Intervention: Diagnostic histopathology reports reviewed by a single pathologist against a checklist
Number of subjects: 1000
Study: 1960551

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week
Number of subjects: 176

Group type: COMPARATOR
Intervention: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week with ASA 600 mg orally four times daily
Number of subjects: 176
Study: 7014349

Group type: EXPERIMENTAL
Intervention: Insulin and glucagon infusion (24 U regular insulin and 2.4 mg glucagon over 12 h daily for 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dextrose solution (200 ml over the same time period)
Number of subjects: 50
Study: 31500494

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC) at 220 mmHg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment at 20 mmHg
Number of subjects: 20
Study: 28576350

Group type: EXPERIMENTAL
Intervention: Sativex Oromucosal Spray (active group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group, n=15)
Number of subjects: 30
Study: 25538173

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, 5-fluorouracil 3200 mg/m2 every 2 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX-6 (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus then 2400 mg/m2 46-h infusion every 2 weeks)
Number of subjects: 80
Study: 23667876

Group type: EXPERIMENTAL
Intervention: Neuroprotector Cortexin added to standard drug therapy
Number of subjects: 0
Study: 21514084

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3687
Study: 19139662

Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 56
Study: 17505806

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard treatment (tizanidine, fluoxetine, vinpocetin, and manual acupressure)
Number of subjects: 126
Study: 12772723

Group type: EXPERIMENTAL
Intervention: New hyper-oxygen transmissible lenses (daily and extended wear)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional lens use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New hyper-oxygen transmissible lenses
Number of subjects: 0
Study: 10761262

Group type: EXPERIMENTAL
Intervention: Maximal androgen deprivation prior to and during definitive radiation therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Technical audits
Number of subjects: 60
Study: 8729674

Group type: EXPERIMENTAL
Intervention: Cr-PI allergen stimulation in PBMC of atopic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cr-PI allergen stimulation in PBMC of normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cr-PI allergen stimulation in T-cell cultures of atopic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cr-PI allergen stimulation in T-cell cultures of normal controls
Number of subjects: 0
Study: 1383434

Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 238

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 20 Gy RT (radiation therapy) after good response to chemotherapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 238
Study: 3904506

Group type: EXPERIMENTAL
Intervention: Near beer (0% alcohol), n = 11
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Near beer (0% alcohol), n = 8
Number of subjects: 85

Group type: COMPARATOR
Intervention: Soft drink, n = 10
Number of subjects: 85
Study: 3315765

Group type: EXPERIMENTAL
Intervention: Intranasal human insulin 100 U/ml with sodium glycocholate 4 % w/v, administered as a spray solution (0.5 U/Kg b.w.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal regular porcine and human insulin 40 U/ml with sodium glycocholate 1 % w/v, administered in drops (0.9 U/Kg b.w.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium glycocholate 4 % w/v
Number of subjects: 0
Study: 29243164

Group type: EXPERIMENTAL
Intervention: Exercise for Cancer Patients (EXCAP©®) - a standardized, individualized, moderate‐intensity, home‐based, six‐week progressive walking and resistance exercise program
Number of subjects: 355

Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 355
Study: 28882167

Group type: EXPERIMENTAL
Intervention: Data Quality Assurance (DQA) protocol implemented through the Data Quality Monitoring and Improvement System (DQMIS)
Number of subjects: 6300

Group type: EXPERIMENTAL
Intervention: DQMIS components including monitoring, evaluation, training, and electronic data collection
Number of subjects: 6300
Study: 26333512

Group type: EXPERIMENTAL
Intervention: Coarse wheat porridge (2‐mm particles)
Number of subjects: 9
Study: 23135419

Group type: EXPERIMENTAL
Intervention: 8-week cognitive behavioral program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 125
Study: 20353621

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) with Motivational Interviewing (MI) and Thought Mapping (TM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Number of subjects: 93
Study: 18758964

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 251
Study: 17002918

Group type: EXPERIMENTAL
Intervention: E(2)‐3beta‐glucoside
Number of subjects: 100

Group type: COMPARATOR
Intervention: E(2)
Number of subjects: 100
Study: 14618093

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 12
Study: 10868622

Group type: EXPERIMENTAL
Intervention: CMV-specific CD8+ CTL response in liver transplant patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CMV-specific CD8+ CTL response in liver transplant patients without symptomatic CMV infection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Antiviral therapy in CMV seronegative recipients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Asymptomatic CMV seronegative patients
Number of subjects: 25
Study: 8899385

Group type: EXPERIMENTAL
Intervention: Recreational exercise more than 1.5 hours per week in the 2 years before diagnosis or referent date
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 1029

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Any intensity exercise at ages 12-21 years
Number of subjects: 1029